Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.28
Abstract: Introduction/Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo in all patient populations, regardless of biomarker status (Coleman et al. Lancet. 2017;390:1949–61). This subgroup analysis examined the effect of the stratification… read more here.
Keywords: pfi; astrazeneca; clovis; clovis astrazeneca ... See more keywords